From: Ophthalmologic compromise following SARS-CoV-2 vaccinations
Patient | 1 | 2 | 3 | 4 | 5 |
---|---|---|---|---|---|
Age (y) | 56 | 89 | 50 | 45 | 53 |
Sex | male | female | male | male | female |
Vaccine brand | 1. AZV | 2. BPV | 2. BPV | 2. BPV | BPV |
LVOD (d) | 7 | 21 | 8 | 10 | 14 |
POD | herpetic keratitis, Iridocyclitis | right central vein occlusion, cataract, glaucoma | herpes uveitis iridocyclitis, COVID-19 | non-arteritic AION | none |
BCVA | 0.02/1.0 | hm/0.09 | 1.0/hm | 1.0/1.0 | 1.0/1.0 |
Diagnosis | exacerbation of herpetic keratitis, iridocyclitis | anterior uveitis | retinal necrosis detachment vitritis | AION | ptosis after SAB ophthalmoparesis |
Side | right | bilateral | left | left | left |
Therapy | AV, ST | ST, antiglaucoma therapy | AV, ST, surgery | vasodilators antiplatelet agents | nm |
Outcome (BCVA) | 0.7/1.0 (1 m) | 0.4/0.4 (4 m) | nm/nm | 1.0/1.0 | nm/nm |